-transparent.png){kind=logo}
Aztreonam was administered to 226 patients with lower respiratory tract infections--primarily pneumonia (181 patients)--due to gram-negative bacilli. The clinical response rate was 93%, and the microbiologic cure rate was 78%. Most patients received 1-g or 2-g intravenous doses of aztreonam three times daily for at least five days. Ninety-eight of the 226 patients were involved in a randomized comparison of aztreonam with tobramycin; the latter drug was administered to a group of 34 patients. The overall microbiologic cure rates for the two drugs were 86% and 71%, respectively. Aztreonam is effective for the treatment of lower respiratory tract infections due to susceptible gram-negative bacilli.
E A Swabb, and
C O Cone, and
J G Muir
January 1985,
Reviews of infectious diseases,
E A Swabb, and
C O Cone, and
J G Muir
June 1988,
Urology,
E A Swabb, and
C O Cone, and
J G Muir
January 1984,
Current medical research and opinion,
E A Swabb, and
C O Cone, and
J G Muir
August 1998,
The Pediatric infectious disease journal,
E A Swabb, and
C O Cone, and
J G Muir
January 1994,
Clinical therapeutics,
E A Swabb, and
C O Cone, and
J G Muir
January 1996,
Clinical therapeutics,
E A Swabb, and
C O Cone, and
J G Muir
May 1988,
The Japanese journal of antibiotics,
E A Swabb, and
C O Cone, and
J G Muir
May 2007,
Antimicrobial agents and chemotherapy,
E A Swabb, and
C O Cone, and
J G Muir
December 1988,
Hinyokika kiyo. Acta urologica Japonica,
E A Swabb, and
C O Cone, and
J G Muir
November 2011,
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
